Abstract
Objectives: Carisbamate (CRS) is a novel monocarbamate compound that possesses antiseizure and neuroprotective properties. However, the mechanisms underlying these actions remain unclear. Here, we tested both direct and indirect effects of CRS on several cellular systems that regulate intracellular calcium concentration [Ca2+]i. Methods: We used a combination of cellular electrophysiologic techniques, as well as cell viability, Store Overload-Induced Calcium Release (SOICR), and mitochondrial functional assays to determine whether CRS might affect [Ca2+]i levels through actions on the endoplasmic reticulum (ER), mitochondria, and/or T-type voltage-gated Ca2+ channels. Results: In CA3 pyramidal neurons, kainic acid induced significant elevations in [Ca2+]i and long-lasting neuronal hyperexcitability, both of which were reversed in a dose-dependent manner by CRS. Similarly, CRS suppressed spontaneous rhythmic epileptiform activity in hippocampal slices exposed to zero-Mg2+ or 4-aminopyridine. Treatment with CRS also protected murine hippocampal HT-22 cells against excitotoxic injury with glutamate, and this was accompanied by a reduction in [Ca2+]i. Neither kainic acid nor CRS alone altered the mitochondrial membrane potential (ΔΨ) in intact, acutely isolated mitochondria. In addition, CRS did not affect mitochondrial respiratory chain activity, Ca2+-induced mitochondrial permeability transition, and Ca2+ release from the ER. However, CRS significantly decreased Ca2+ flux in human embryonic kidney tsA-201 cells transfected with Cav3.1 (voltage-dependent T-type Ca2+) channels. Significance: Our data indicate that the neuroprotective and antiseizure activity of CRS likely results in part from decreased [Ca2+]i accumulation through blockade of T-type Ca2+ channels.
Original language | English |
---|---|
Pages (from-to) | 617-626 |
Number of pages | 10 |
Journal | Epilepsia |
Volume | 58 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2017 |
Bibliographical note
Publisher Copyright:Wiley Periodicals, Inc. © 2017 International League Against Epilepsy
Funding
This work is supported by Johnson & Johnson Pharmaceutical Research (JMR), the Barrow Neurological Foundation (DYK), National Institutes of Health (NIH) grant NS070261 (JMR, DYK), the Alberta Children's Hospital Research Institute (SN, JMR), the Canada Foundation for Innovation (SRWC), the Heart and Stroke Foundation/Libin Professorship in Cardiovascular Research (SRWC), the Natural Sciences and Engineering Research Council of Canada (SRWC), and the Canadian Institutes of Health Research (SRWC, GWZ, JMR). FXZ was supported by a fellowship from Alberta Innovates Health Solutions.
Funders | Funder number |
---|---|
DYK | |
Heart and Stroke Foundation/Libin | |
JMR Barker Foundation | |
SRWC | |
National Institutes of Health (NIH) | |
National Institute of Neurological Disorders and Stroke | R01NS070261 |
Barrow Neurological Foundation | |
Alberta Children's Hospital Research Institute | |
Johnson and Johnson Pharmaceutical Research and Development | |
Canadian Institutes of Health Research | |
Natural Sciences and Engineering Research Council of Canada | |
Alberta Innovates - Health Solutions | |
Canada Foundation for Innovation |
Keywords
- Calcium
- Carisbamate
- Endoplasmic reticulum
- Kainic acid
- Mechanism
- Mitochondria
- Neuroprotection
- Ryanodine receptor
- T-type calcium channel
ASJC Scopus subject areas
- Neurology
- Clinical Neurology